Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX in Advanced/Metastatic Transitional Cell Carcinoma
NCT00127595Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Jan 2002
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and gemcitabine in transitional cell carcinoma (TCC), sponsored by Gustave Roussy. Primary endpoint: Response Rate. Started Jan 2002; status: terminated.
02
Drugs
oxaliplatingemcitabine
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT00127595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127595.